Rome, Italy 30 August 2016: The antiplatelet drugs prasugrel and ticagrelor had similar safety and efficacy among patients with acute myocardial infarction and ST segment elevations (STEMI), according to results of PRAGUE-18, the first randomised, head-to-head comparison of the drugs.
"Our findings confirm previous indirect - non-randomized- comparisons of these two drugs, based on analyses of various registries," commented Petr Widimsky MD, DrSc, from the Cardiocenter of Charles University, in Prague, Czech Republic. "Thus, both drugs are very effective and safe and significantly contribute to the excellent outcomes of patients with acute myocardial infarction in modern cardiology."
The Hot Line study, presented at ESC Congress 2016, randomized 1,230 STEMI patients to receive either prasugrel or ticagrelor prior to primary percutaneous coronary intervention (pPCI).
The primary end-point was defined as death, re-infarction, urgent target vessel revascularization, stroke, serious bleeding requiring transfusion, or prolonged hospitalization at 7 days.
The trial was halted prematurely after an interim analysis showed no difference in the rate of this endpoint between groups (4.0% and 4.1% in the prasugrel and ticagrelor groups, respectively; P=0.939).
There was also no difference between groups in the rate of the key secondary end-point, composed of cardiovascular death, non-fatal myocardial infarction or stroke within 30 days (2.7% and 2.5%, respectively; P=0.864).
"These study results offer more freedom to clinicians to select the antiplatelet agent added on top of aspirin for patients with STEMI who receive dual antiplatelet therapy," commented Prof. Widimsky.
Final follow-up will be at 1 year for all patients, and will be completed in 2017.
The PRAGUE acronym refers to a series of academic randomized trials coordinated by the Cardiocenter, Charles University Prague, starting with PRimary Angioplasty in patients with myocardial infarction transferred from General community hospitals to angioplasty Units of tertiary cardiology centers with or without Emergency thrombolysis (2000).
###
Notes to editors
Sources of funding: Administrative costs were covered by the Charles University Cardiovascular Research Program P35.
Disclosures: The investigators have no relevant disclosures.
ESC Press Office
For background information, please contact the ESC Press Office at media@escardio.org.
For press enquiries, please contact, the Media & Press Coordinator, Jacques Olivier Costa: +393427028575
For independent comment on site, please contact the ESC Spokesperson coordinator, Celine Colas: +393402405148
To access all the scientific resources from the sessions during the congress, visit ESC Congress 365.
About the European Society of Cardiology
The European Society of Cardiology brings together health care professionals from more than 120 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.
About ESC Congress 2016
ESC Congress is the world's largest gathering of cardiovascular professionals contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2016 takes place 27 to 31 August at the Fiera di Roma in Rome, Italy. The scientific programme is here. More information is available from the ESC Press Office at press@escardio.org
This press release accompanies both a presentation and an ESC press conference at the ESC Congress 2016. Edited by the ESC from material supplied by the investigators themselves, this press release does not necessarily reflect the opinion of the European Society of Cardiology. The content of the press release has been approved by the presenter.